In most Dutch melanoma families, a founder deletion in the melanoma susceptibility gene CDKN2A (which encodes p16) is present. This founder deletion (p16-Leiden) accounts for a significant proportion of the increased melanoma risk. However, it does not account for the Atypical Nevus (AN) phenotype that segregates in both p16-Leiden carriers and non-carriers. The AN-affected p16-Leiden family members are therefore a unique valuable resource for unraveling the genetic etiology of the AN phenotype, which is considered both a risk factor and a precursor lesion for melanoma. In this study, we performed a genome-wide scan for linkage in four p16-Leiden melanoma pedigrees, classifying family members with five or more AN as affected. The strongest evidence for an atypical nevus susceptibility gene was mapped to chromosome band 7q21.3 (two-point LOD score=2.751), a region containing candidate gene CDK6.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ejhg.2008.72 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic variants.
J Med Genet
April 2021
Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
Background: Pathogenic variants in the gene are generally associated with the development of melanoma and pancreatic ductal adenocarcinoma (PDAC), but specific genotype-phenotype correlations might exist and the extent of PDAC risk is not well established for many variants.
Methods: Using the Dutch national familial melanoma database, we identified all families with a pathogenic variant and investigated the occurrence of PDAC within these families. We also estimated the standardised incidence ratio and lifetime PDAC risk for carriers of a highly prevalent variant in these families.
Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.
Eur J Med Genet
March 2020
Department of Surgery, Erasmus MC - University Medical Center, Rotterdam, the Netherlands.
Article Synopsis
- Familial atypical multiple mole melanoma (FAMMM) syndrome is a genetic condition linked to multiple atypical moles and an increased likelihood of melanoma and pancreatic cancer due to mutations in the CDKN2A gene.
- The p16-Leiden variant of CDKN2A is particularly concerning as it significantly heightens cancer risks, including developing melanomas.
- A study of two patients with the p16-Leiden variant who also developed esophageal squamous cell cancer showed evidence of tumor cells losing the normal CDKN2A allele, indicating a link between FAMMM syndrome and this type of cancer.
Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
Am J Surg Pathol
September 2019
Departments of Pathology.
Germline mutations in CDKN2A result in Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM), which is associated with an increased risk for pancreatic ductal adenocarcinoma and melanoma. CDKN2A is somatically inactivated in multiple neoplasms, raising the possibility that, although the data are not conclusive, germline CDKN2A mutation may also impose an increased risk for other neoplasms. We present a patient with a CDKN2A germline mutation (p16-Leiden mutation) and mosaicism for neurofibromatosis type 2, who presented with a small asymptomatic pancreatic lesion, detected during endoscopic ultrasound screening of the pancreas.
View Article and Find Full Text PDFAssessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
Fam Cancer
October 2019
Department of Dermatology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Carriers of pathogenic variants in CDKN2A have a 70% life-time risk of developing melanoma and 15-20% risk of developing pancreatic cancer (PC). In the Netherlands, a 19-bp deletion in exon 2 of CDKN2A (p16-Leiden mutation) accounts for most hereditary melanoma cases. Clinical experience suggests variability in occurrence of melanoma and PC in p16-Leiden families.
View Article and Find Full Text PDFPancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
BMC Res Notes
June 2015
Department of Clinical Genetics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome in the Netherlands. Individuals with this mutation are at increased risk for developing melanoma of the skin, as well as pancreatic cancer. However, there is a notable interfamilial variability in the occurrence of pancreatic cancer among p16-Leiden families.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!